Loading...

Palla Pharma

ASX:PAL
Snowflake Description

Reasonable growth potential with mediocre balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
PAL
ASX
A$96M
Market Cap
  1. Home
  2. AU
  3. Pharmaceuticals & Biotech
Company description

Palla Pharma Limited produces and distributes narcotic raw materials, active pharmaceutical ingredients, and finished dosage formulations for pharmaceutical markets in Australia and Norway. The last earnings update was 133 days ago. More info.


Add to Portfolio Compare Print
  • Palla Pharma has significant price volatility in the past 3 months.
PAL Share Price and Events
7 Day Returns
-0.4%
ASX:PAL
7.8%
AU Life Sciences
-0.1%
AU Market
1 Year Returns
-12.3%
ASX:PAL
-7.4%
AU Life Sciences
5.2%
AU Market
PAL Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Palla Pharma (PAL) -0.4% 7% -15.8% -12.3% -57.6% -
AU Life Sciences 7.8% 9.8% 0.2% -7.4% -42.1% -88.4%
AU Market -0.1% 2.4% 6.5% 5.2% 19.8% 11.8%
1 Year Return vs Industry and Market
  • PAL underperformed the Life Sciences industry which returned -7.4% over the past year.
  • PAL underperformed the Market in Australia which returned 5.2% over the past year.
Price Volatility
PAL
Industry
5yr Volatility vs Market

PAL Value

 Is Palla Pharma undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Palla Pharma. This is due to cash flow or dividend data being unavailable. The share price is A$1.145.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Palla Pharma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Palla Pharma's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:PAL PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in AUD A$-0.09
ASX:PAL Share Price ** ASX (2019-07-18) in AUD A$1.15
Global Life Sciences Industry PE Ratio Median Figure of 53 Publicly-Listed Life Sciences Companies 38.54x
Australia Market PE Ratio Median Figure of 546 Publicly-Listed Companies 16.19x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Palla Pharma.

ASX:PAL PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:PAL Share Price ÷ EPS (both in AUD)

= 1.15 ÷ -0.09

-13.44x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Palla Pharma is loss making, we can't compare its value to the Global Life Sciences industry average.
  • Palla Pharma is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does Palla Pharma's expected growth come at a high price?
Raw Data
ASX:PAL PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -13.44x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
59.7%per year
Global Life Sciences Industry PEG Ratio Median Figure of 39 Publicly-Listed Life Sciences Companies 2.61x
Australia Market PEG Ratio Median Figure of 361 Publicly-Listed Companies 1.34x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Palla Pharma, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Palla Pharma's assets?
Raw Data
ASX:PAL PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in AUD A$0.61
ASX:PAL Share Price * ASX (2019-07-18) in AUD A$1.15
Australia Life Sciences Industry PB Ratio Median Figure of 9 Publicly-Listed Life Sciences Companies 5.26x
Australia Market PB Ratio Median Figure of 1,693 Publicly-Listed Companies 1.68x
ASX:PAL PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:PAL Share Price ÷ Book Value per Share (both in AUD)

= 1.15 ÷ 0.61

1.88x

* Primary Listing of Palla Pharma.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Palla Pharma is good value based on assets compared to the AU Life Sciences industry average.
X
Value checks
We assess Palla Pharma's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Life Sciences industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Life Sciences industry average (and greater than 0)? (1 check)
  5. Palla Pharma has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

PAL Future Performance

 How is Palla Pharma expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
59.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Palla Pharma expected to grow at an attractive rate?
  • Palla Pharma's earnings growth is expected to exceed the low risk savings rate of 2.3%.
Growth vs Market Checks
  • Palla Pharma's earnings growth is expected to exceed the Australia market average.
  • Palla Pharma's revenue growth is expected to exceed the Australia market average.
Annual Growth Rates Comparison
Raw Data
ASX:PAL Future Growth Rates Data Sources
Data Point Source Value (per year)
ASX:PAL Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 59.7%
ASX:PAL Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 17.7%
Global Life Sciences Industry Earnings Growth Rate Market Cap Weighted Average 16.4%
Global Life Sciences Industry Revenue Growth Rate Market Cap Weighted Average 8.3%
Australia Market Earnings Growth Rate Market Cap Weighted Average 7.3%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:PAL Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:PAL Future Estimates Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-12-31 100 13 1
2021-12-31 90 14 10 1
2020-12-31 77 13 8 1
2019-12-31 63 5 2 1
ASX:PAL Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2018-12-31 46 -15 -7
2018-09-30 42 -12 -10
2018-06-30 38 -9 -13
2018-03-31 30 -11 -15
2017-12-31 22 -13 -17
2017-09-30 17 -15 -16
2017-06-30 12 -16 -15
2017-03-31 10 -15 -15
2016-12-31 8 -14 -14
2016-09-30 5 -15 -19
2016-06-30 3 -17 -25
2016-03-31 2 -16 -25

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Palla Pharma's earnings are expected to grow significantly at over 20% yearly.
  • Palla Pharma's revenue is expected to grow by 17.7% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:PAL Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Palla Pharma Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:PAL Future Estimates Data
Date (Data in AUD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-12-31
2021-12-31 0.13 0.13 0.13 1.00
2020-12-31 0.09 0.09 0.09 1.00
2019-12-31 0.03 0.03 0.03 1.00
ASX:PAL Past Financials Data
Date (Data in AUD Millions) EPS *
2018-12-31 -0.09
2018-09-30 -0.12
2018-06-30 -0.16
2018-03-31 -0.20
2017-12-31 -0.23
2017-09-30 -0.25
2017-06-30 -0.26
2017-03-31 -0.27
2016-12-31 -0.27
2016-09-30 -0.37
2016-06-30 -0.48
2016-03-31 -0.50

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Palla Pharma is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Palla Pharma's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Global market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Global market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Palla Pharma has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

PAL Past Performance

  How has Palla Pharma performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Palla Pharma's growth in the last year to its industry (Life Sciences).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Palla Pharma does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Palla Pharma's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Palla Pharma's 1-year growth to the Global Life Sciences industry average as it is not currently profitable.
Earnings and Revenue History
Palla Pharma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Palla Pharma Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:PAL Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 46.46 -6.91 15.40 0.27
2018-09-30 42.44 -9.96 15.27 0.24
2018-06-30 38.42 -13.02 15.13 0.21
2018-03-31 30.04 -14.86 12.91 0.29
2017-12-31 21.67 -16.69 10.69 0.37
2017-09-30 16.88 -15.95 9.31 0.97
2017-06-30 12.08 -15.20 7.94 1.57
2017-03-31 9.85 -14.61 7.91 1.43
2016-12-31 7.61 -14.02 7.88 1.29
2016-09-30 5.09 -19.30 7.57 0.68
2016-06-30 2.56 -24.57 7.25 0.06
2016-03-31 2.41 -25.24 8.16 0.06
2015-12-31 2.26 -25.90 9.06 0.05
2015-09-30 2.85 -21.36 8.63 0.02
2015-06-30 3.44 -16.81 8.20
2015-03-31 5.66 -15.63 6.48
2014-12-31 7.88 -14.44 4.76
2013-12-31 15.30 -6.79 4.36
2012-12-31 9.68 -12.36 4.67

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Palla Pharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Palla Pharma has efficiently used its assets last year compared to the Global Life Sciences industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Palla Pharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Palla Pharma's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Life Sciences industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Palla Pharma has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

PAL Health

 How is Palla Pharma's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Palla Pharma's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Palla Pharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Palla Pharma's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Palla Pharma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Palla Pharma Company Filings, last reported 6 months ago.

ASX:PAL Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 49.30 22.87 1.90
2018-09-30 49.30 22.87 1.90
2018-06-30 51.35 5.00 1.40
2018-03-31 51.35 5.00 1.40
2017-12-31 53.25 5.08 3.64
2017-09-30 53.25 5.08 3.64
2017-06-30 44.18 0.17 10.72
2017-03-31 44.18 0.17 10.72
2016-12-31 10.72 19.92 0.62
2016-09-30 10.72 19.92 0.62
2016-06-30 13.37 17.34 1.16
2016-03-31 13.37 17.34 1.16
2015-12-31 20.63 5.87 0.57
2015-09-30 20.63 5.87 0.57
2015-06-30 38.04 8.60 6.66
2015-03-31 38.04 8.60 6.66
2014-12-31 11.60 17.92 0.82
2013-12-31 14.69 18.78 0.34
2012-12-31 2.77 27.06 1.47
  • Palla Pharma's level of debt (46.4%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (128.1% vs 46.4% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Palla Pharma has less than a year of cash runway based on current free cash flow.
  • Palla Pharma has less than a year of cash runway if free cash flow continues to reduce at historical rates of -20.6% each year.
X
Financial health checks
We assess Palla Pharma's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Palla Pharma has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

PAL Dividends

 What is Palla Pharma's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Palla Pharma dividends. Estimated to be 0% next year.
If you bought A$2,000 of Palla Pharma shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Palla Pharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Palla Pharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:PAL Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Global Life Sciences Industry Average Dividend Yield Market Cap Weighted Average of 23 Stocks 0.5%
Australia Market Average Dividend Yield Market Cap Weighted Average of 415 Stocks 4%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.5%
Australia Bottom 25% Dividend Yield 25th Percentile 2.5%
Australia Top 25% Dividend Yield 75th Percentile 5.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ASX:PAL Future Dividends Estimate Data
Date (Data in A$) Dividend per Share (annual) Avg. No. Analysts
2022-12-31 0.00 1.00
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Palla Pharma has not reported any payouts.
  • Unable to verify if Palla Pharma's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Palla Pharma's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Palla Pharma has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Palla Pharma's dividends in 3 years as they are not expected to pay a notable one for Australia.
X
Income/ dividend checks
We assess Palla Pharma's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Palla Pharma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Palla Pharma has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

PAL Management

 What is the CEO of Palla Pharma's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jarrod Ritchie
COMPENSATION A$904,475
CEO Bio

Mr. Jarrod Ritchie, BSc (Hons) serves as the Chief Executive Officer and Managing Director of TPI Enterprises Ltd. Mr. Ritchie founded TPI Enterprises Ltd in 2004 and has been its Executive Director since February 5, 2004.

CEO Compensation
  • Jarrod's compensation has increased whilst company is loss making.
  • Jarrod's remuneration is higher than average for companies of similar size in Australia.
Management Team

Jarrod Ritchie

TITLE
Founder
COMPENSATION
A$904K

Brendan Middleton

TITLE
Chief Financial Officer
COMPENSATION
A$349K
TENURE
2.1 yrs

Jaime Pinto

TITLE
Company Secretary
TENURE
2.8 yrs
Board of Directors Tenure

Average tenure and age of the Palla Pharma board of directors in years:

3.1
Average Tenure
52
Average Age
  • The tenure for the Palla Pharma board of directors is about average.
Board of Directors

Simon Moore

TITLE
Independent Non-Executive Chairman
COMPENSATION
A$111K
AGE
52
TENURE
1.2 yrs

Jarrod Ritchie

TITLE
Founder
COMPENSATION
A$904K
TENURE
15.4 yrs

Stuart Black

TITLE
Independent Non-Executive Director
COMPENSATION
A$88K
TENURE
3.1 yrs

Todd Barlow

TITLE
Non Executive Director
COMPENSATION
A$77K
AGE
40
TENURE
4.1 yrs

Sue MacLeman

TITLE
Independent Non-Executive Director
COMPENSATION
A$5K
AGE
55
TENURE
0.7 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
23. Jul 18 Buy Bendigo and Adelaide Bank Limited, Asset Management Arm Company 07. Jun 17 20. Jul 18 4,057,618 A$2.20 A$8,926,759
X
Management checks
We assess Palla Pharma's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Palla Pharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

PAL News

Simply Wall St News

PAL Company Info

Description

Palla Pharma Limited produces and distributes narcotic raw materials, active pharmaceutical ingredients, and finished dosage formulations for pharmaceutical markets in Australia and Norway. It also produces and distributes poppy seeds to culinary markets. The company was formerly known as TPI Enterprises Limited and changed its name to Palla Pharma Limited in June 2019. The company was founded in 2004 and is based in Docklands, Australia.

Details
Name: Palla Pharma Limited
PAL
Exchange: ASX
Founded: 2004
A$95,681,000
81,085,594
Website: http://www.tpienterprises.com
Address: Palla Pharma Limited
Tower 4,
727 Collins Street,
Docklands,
Victoria, 3008,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX PAL Ordinary Shares Australian Securities Exchange AU AUD 13. Aug 2015
Number of employees
Current staff
Staff numbers
0
Palla Pharma employees.
Industry
Life Sciences Tools and Services
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/18 10:39
End of day share price update: 2019/07/18 00:00
Last estimates confirmation: 2019/06/26
Last earnings filing: 2019/03/07
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.